Tag: NOTV

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inotiv (NOTV – Research Report), Ironwood Pharma (IRWD – Research Report) and Aquestive Therapeutics (AQST – Research Report) with bullish sentiments.

Inotiv (NOTV)

In a report released today, Frank Takkinen from Lake Street upgraded Inotiv to Buy, with a price target of $4.00. The company’s shares closed last Friday at $1.58, close to its 52-week low of $1.23.

According to TipRanks.com, Takkinen is a 2-star analyst with an average return of 0.0% and a 45.1% success rate. Takkinen covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, REPRO-MED Systems, and Lemaitre Vascular.

Currently, the analyst consensus on Inotiv is a Moderate Buy with an average price target of $4.00.

See today’s best-performing stocks on TipRanks >>

Ironwood Pharma (IRWD)

Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Ironwood Pharma today. The company’s shares closed last Friday at $4.02, close to its 52-week low of $3.79.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 16.0% and a 53.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Diamedica Therapeutics, and Fennec Pharmaceuticals.

Currently, the analyst consensus on Ironwood Pharma is a Moderate Buy with an average price target of $10.67.

Aquestive Therapeutics (AQST)

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Aquestive Therapeutics, with a price target of $7.00. The company’s shares closed last Friday at $4.72.

According to TipRanks.com, Flaten is a 3-star analyst with an average return of 1.4% and a 45.3% success rate. Flaten covers the Healthcare sector, focusing on stocks such as Checkpoint Therapeutics, Diamedica Therapeutics, and Achieve Life Sciences.

Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.80, implying a 91.0% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $9.00 price target.

Read More on NOTV:

• Inotiv upgraded to Buy from Hold at Lake Street
• Inotiv Bolsters Financial Position for Future Growth Opportunities
• Inotiv amends credit agreement, secures additional liquidity
• Inotiv reports Q3 EPS ($1.00), consensus (83c)
• Inotiv, Inc. (NOTV) Q3 Earnings Cheat Sheet